SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: margie who wrote (4434)6/5/1998 10:51:00 AM
From: ALL  Read Replies (2) of 6136
 
PW Growth & Tech Conference Correction

In message 4431 point 4), I stated that "Viracept has a lower market share among whites than blacks and hispanics." I MEANT, Viracept has a lower market share among blacks and hispanics than whites.

BTW, AGPH is searching for a late-stage HIV drug to expand its HIV franchise and leverage its sales force. Mr. Johnson said, "This is much easier said than done. Most of the biotechs at this conference will tell you the same thing." (They are looking to diversify their product base) Responding to a question, "We are both evaluating and talking with potential suitors."

Question: Does late state HIV drug mean one in the later stages of approval or one in the later stages of its market life, such as an opportunistic infection drug?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News